Vaxxas, an Australian biotechnology company that’s setting up operations in Cambridge, said today it has initiated a research collaboration with Merck. Under the agreement, Merck will pay an undisclosed upfront fee and will provide funding to Vaxxas to conduct research evaluating the potential of using Vaxxas’ Nanopatch platform for a Merck vaccine candidate. Vaxxas will be eligible to receive additional milestone and royalty payments. The Nanopatch platform induces “robust immune system activation by targeting vaccine to the abundant immunological cells immediately below the surface of the skin,” Vaxxas said.
